Synlogic Inc (SYBX.OQ)
23 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|62||2012||Chairman of the Board|
|2017||President, Chief Executive Officer, Director|
|2017||Chief Financial Officer, Secretary|
|53||2017||Chief Operating Officer - Head of Corporate Development|
|2017||Chief Scientific Officer|
- BRIEF-Synlogic Receives Fast-Track Designation For Synb1618, A Synthetic Biotic Medicine For Treatment Of Phenylketonuria
- BRIEF-Synlogic Doses First Subject In Phase 1/2A Trial Of Synb1618 For Treatment Of Phenylketonuria
- BRIEF-Hawkes Bay Master Investors (Cayman) L.P. Reports 5.30 Pct Passive Stake In Synlogic As Of April 06, 2018
- BRIEF-Synlogic Agrees To Sell 3.3 Mln Shares To Mutual Fund Investor In Registered Direct Offering
- BRIEF-Synlogic Doses First Patient In Phase 1b/2a Trial Of SYNB1020 For Treatment Of Hyperammonemia In Patients With Cirrhosis